Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue SUPPL.3, 2012, Pages 108-111

  Nakajima, Shigemi ^a   Inoue, Hisayuki ^b   Inoue, Tetsuya ^a   Maruoka, Yuri ^a  

^a Social Insurance Shiga Hospital   (Japan)

^b Inoue Clinic   (Japan)

Author keywords

CYP2C19 genotype; Helicobacter pylori; High dose PPI therapy; Multiple antibiotic resistance; Tailor made quadruple therapy

Indexed keywords

AMOXICILLIN; BISMUTH NITRATE; CLARITHROMYCIN; CYTOCHROME P450 2C19; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MINOCYCLINE; RABEPRAZOLE;

ADULT; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CASE REPORT; CHRONIC GASTRITIS; ENDOSCOPY; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; GENOTYPE; HELICOBACTER INFECTION; HUMAN; INFORMED CONSENT; PRIORITY JOURNAL; STOMACH BIOPSY; TREATMENT DURATION; TREATMENT FAILURE; UREA BREATH TEST;

EID: 84859401623     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07069.x     Document Type: Article

References (18)

1. Nakajima S, Graham DY, Hattori T, Bamba T. Strategy for treatment of Helicobacter pylori infection in adults. II: practical policy in 2000. Curr. Pharm. Des. 2000; 6: 1515-29.
2. Asaka M, Kato M, Takahashi S etal. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
3. Tanigawara Y, Aoyama N, Kita T etal. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 1999; 66: 528-34.
4. van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996; 1: 6-19.
5. Nasu M, Nishino T, Azuma T etal. Report of the committee on the antibiotics-susceptibility test in Helicobacter pylori eradication therapy. Jpn. J. Chemother. 2000; 48: 561-7.
6. Boyanova L. Comparative evaluation of two methods for testing metronidazole susceptibility of Helicobacter pylori in routine practice. Diagn. Microbiol. Infect. Dis. 1999; 35: 33-6.
7. Nakajima S, Yamaguchi T, Hidaka T etal. [Two-week therapy of the same drugs for the failure of the first therapy with 1-week lansoprazole, amoxicillin and clarithromycin to Helicobacter pylori infection. Nippon Shokakibyo Gakkai Zasshi (Journal of the Japanese Society of Gastroenterology) 2004; 101 (Suppl.): 691. (In Japanese.)
8. Zullo A, Vaira D, Vakil N etal. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment. Pharmacol. Ther. 2003; 17: 719-26.
9. Craig WA. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am. J. Med. 2004; 2 (Suppl. 3A): 16S-22S.
10. Phillips RH, Whitehead MW, Lacey S, Champion M, Thompson RP, Powell JJ. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy. Helicobacter 2000; 5: 176-82.
11. Whitehead MW, Phillips RH, Sieniawska CE etal. Double-blind comparison of absorbable colloidal bismuth subcitrate and nonabsorbable bismuth subnitrate in the eradication of Helicobacter pylori and the relief of nonulcer dyspepsia. Helicobacter 2000; 5: 169-75.
12. Carvalho AF, Fiorelli LA, Jorge VN etal. Addition of bismuth subnitrate to omeprazole plus amoxycillin improves eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. 1998; 12: 557-61.
13. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. 2001; 70: 484-92.
14. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective. Aliment. Pharmacol. Ther. 2003; 18: 1175-6.
15. Furuta T, Takashima M, Shirai N etal. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin. Pharmacol. Ther. 2000; 67: 684-9.
16. Saitoh T, Fukushima Y, Otsuka H etal. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 2002; 16: 1811-17.
17. Liou JM, Chang CY, Sheng WH etal. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob. Agents Chemother. 2011; 55: 1123-9.
18. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol. Clin. North Am. 2010; 39: 465-80.